Tetracycline Allergy

Leslie A. Hamilton 1 and Anthony J. Guarascio 2,*

1 Department of Clinical Pharmacy and Translational Science, the University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN 37909, USA
2 Division of Pharmacy Practice, Duquesne University School of Pharmacy, 600 Forbes Avenue, Pittsburgh, PA 15282, USA
* Correspondence: guarascioa@duq.edu; Tel.: +1-412-396-1296

Received: 29 June 2019; Accepted: 30 July 2019; Published: 3 August 2019

Abstract: Despite the widespread use of tetracycline antibiotics since the late 1940s, tetracycline hypersensitivity reactions have rarely been described in the literature. A comprehensive PubMed search was performed, including allergic and serious adverse reactions attributed to the tetracyclines class of antibiotics. Of the evaluated tetracycline analogs, minocycline was attributed to the greatest overall number and severity of serious adverse events reported in the literature, with notable reactions primarily reported as respiratory and dermatologic in nature. Reactions to tetracycline have also been well described in the literature, and although dermatologic reactions are typically less severe in comparison with minocycline and doxycycline, various reports of anaphylactic reactions exist. Although doxycycline has been noted to have had the fewest reports of severe allergic reactions, rare descriptions of life-threatening reactions are still reported in the literature. Allergic reactions regarding tetracyclines are rare; however, adverse reaction type, severity, and frequency among different tetracycline analogs is somewhat variable. A consideration of hypersensitivity and adverse reaction incidence should be performed prior to the selection of individual tetracycline entities.

Keywords: tetracycline; doxycycline; minocycline; allergy; allergic reaction

1. Introduction

Tetracyclines were first discovered in the 1940s [1] and are still widely utilized antibiotic agents with a unique spectrum of activity and clinical utility for a variety of infections. Tetracycline, doxycycline, and minocycline have been extensively studied, while doxycycline and minocycline are most frequently used due to tolerability and dosing considerations. Demeclocycline is a commercially available tetracycline rarely deployed for its antibacterial activity; rather, it is sometimes used for treatment of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) [2] and therefore will not be formally reviewed. At this time, newer, enhanced spectrum tetracycline derivatives such as tigecycline and recently approved agents such as eravacycline, sarecycline, and omadacycline, have more limited data regarding their use.

Tetracyclines display broad activity against Gram-positive aerobic bacteria and some Gram-negative bacteria, various atypical pathogens, and some protozoan parasites. A common indication for the use of doxycycline, either alone or in combination with a beta-lactam antibiotic, includes the empiric treatment of community-acquired pneumonia due to Streptococcus pneumoniae and atypical pathogen activity [3]. Doxycycline and minocycline activity against community-acquired methicillin-resistant Staphylococcus aureus (MRSA) isolates provides a valuable utility for the treatment of acute bacterial skin and skin structure infections (ABSSIs) [4,5].

Doxycycline and minocycline are also first-line options for the treatment of acne due to their efficacy against Propionobacterium acnes [6]. Doxycycline is an agent commonly utilized for various
sexually transmitted infections such as chlamydia [7], as well as tickborne infections borelliosis (such as Lyme disease), ehrlichiosis, and rickettsial diseases (such as Rocky Mountain spotted fever) [8]. While newer tetracycline agents such as tigecycline offer an extended spectrum of activity compared with older agents, these are typically utilized as alternatives rather than first line options for resistant or polymicrobial infections.

2. Materials and Methods

A comprehensive literature search was completed using PubMed from 1956 to present. The search terms included tetracycline, minocycline, doxycycline, tigecycline, adverse event, allergy, sensitivity, and allergic reaction. Only articles in English were included.

3. Results and Discussion

The literature evaluation and discussion is divided into sections by each medication, including tetracycline, minocycline, and doxycycline.

3.1. Tetracycline

Tetracycline has a long track record of the successful treatment of a variety of infections such as acne, Helicobacter pylori infection, sexually transmitted infections, and periodontitis. In current clinical practice, tetracycline use is often limited due to preferential selection of newer tetracycline derivatives such as doxycycline. Although there are various reasons for this, both administration (four times daily for tetracycline versus twice daily for doxycycline) and better tolerability with doxycycline have been well described [9]. Chlortetracycline, the first tetracycline antibiotic identified, is no longer utilized in humans, rather, it still holds utility as a veterinary antibiotic [9]. Due to its lack of current use, it was excluded from this review, despite its shared characteristics of both allergic reaction and cross-reactivity with other tetracyclines.

Most of the primary literature data regarding tetracycline reactions is described in case reports and case series studies. The most commonly reported reaction due to tetracycline administration is a fixed drug reaction. While the site of this reaction varies, including the extremities, chest, and face, and a multitude of reports describe penile lesions [10–14]. Fixed drug reactions have rarely been noted intraorally or on the entire body [15,16]. In addition, many patients had previously received tetracycline prior to the fixed drug incident, with one patient receiving up to five documented courses prior to the reaction [17]. Notably absent from the literature are more severe and widespread dermatologic reactions such as Stevens-Johnson syndrome (SJS) and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), which has rarely been associated with other tetracycline derivatives such as minocycline and doxycycline.

Since one of the hallmarks of a fixed drug reaction is local recurrence upon re-challenge of the offending agent, various studies chose to perform this tetracycline re-challenge when feasible and appropriate. High reactivity rates with the re-administration of tetracycline have been reported. Delaney et al. 1970 described a second dermatologic reaction to an oral challenge dose administered shortly after an initial fixed drug reaction affecting the glans penis with dysuria [14]. On various occasions, patients are prescribed subsequent courses of oral tetracycline years later for a different infection following a reaction. One such case also yielded a similar fixed drug reaction on the thigh, buttocks, and penis [18]. Yap et al. describes a case of tetracycline-induced solar urticaria that developed within five minutes of patient exposure to sunlight [19]. Follow-up photo-testing as a diagnostic challenge revealed light-induced eruptions, while these reactions were resolved within a week of tetracycline discontinuation [19]. Likewise, a case report described an atypical acneiform cutaneous eruption that occurred during primary tetracycline exposure, as well as with two different episodes of re-administration [20]. There are several others dermatologic reports that are included in Table 1 [21–24].
Table 1. Dermatological adverse effects caused by tetracycline.

| Publication   | Patient(s)               | Manifestations                                                                 | Treatment and Outcome |
|---------------|--------------------------|--------------------------------------------------------------------------------|-----------------------|
| Ziprowski 1958| 35 yo female             | Erythematous rash on face, upper extremities, and entire body including mouth and tongue mucous membranes, joint pain | Antihistamine, survived |
| Calnan 1960   | 52 yo male               | Vesicular eruptions with erythema, edema, and papules and pustules of hands and feet | Calamine lotion, phenobarbitone, diphenhydramine, survived |
| Dubowitz 1964 | 5 yo male                | Urticarial rash followed by swelling and pigmentation of face, eyelids, and extremities | Not reported, survived |
| Minkin 1969   | 38 yo male               | Erythema, pruritic and pigmented patches, fixed drug reaction of finger webs of hand | Not reported, survived |
| Broden 1970   | Male, age unknown        | Erythema, pruritic patch on index finger and penis, fixed drug reaction           | Not reported, survived |
| Delaney 1970  | 49 yo male               | Erythema, pruritic rash on penis                                               | Steroid cream, antihistamine, survived |
| Tarnowski 1970| 44 yo female             | Erythematous, pigmented slightly raised plaques on extremities                 | Not reported, survived |
| Bean 1971     | 30 yo male               | Acneiform eruption, superficial follicular pustules on neck, chest, extremities | Prednisone, calamine lotion, survived |
| Csonka 1971   | 24 yo male; 29 yo male; 34 yo male; 21 yo male | All: erythematous fixed drug eruption on penis                                   | Not reported, survived |
| Armati 1973   | 36 yo male               | Erythema, pruritic macules on penis, buttocks and thighs                         | Hydrocortisone cream, survived |
| Parish 1978   | 29 yo female             | Erythema, edematous plaque, pulsating fixed drug reaction of arm                 | Betamethasone gel, survived |
| Fiumara 1981  | 29 yo male; 22 yo male    | Pigmented penile rash, fixed drug eruption (both)                                | Not reported, survived |
| Murray 1982   | 46 yo male               | Erythematous reaction on left palate, intraoral fixed drug reaction              | Not reported, survived |
| Dodds 1985    | 77 yo male; 38 yo male; 56 yo male | All: balanitis, erythema, swelling, fixed drug reaction of glans penis; one with hyperpigmented lesions; one with ulcerations and hemorrhagic rash | Not reported, survived |
| Yap 2000      | 28 yo female             | Solar urticaria with popular eruption of perioral and eyelid regions, reaction prominent beyond borders of clothing | Not reported, survived |

Overall, IgE-mediated immediate-type anaphylactic hypersensitivity reactions due to tetracycline use are rare and typically not fatal when an adequate intervention is performed (Table 2). When reported, most anaphylactic reactions noted by case reports have occurred within 10–45 min following oral or intravenous administration of tetracycline, while one case of anaphylaxis following intramuscular administration occurred rapidly in less than 20 s [25]. Since anaphylaxis can occur once a patient reacts to an antigen for which they have been previously sensitized, various cases of tetracycline-induced anaphylaxis reported prior tetracycline exposure [26,27].

Only one case report described re-challenging the patient’s anaphylactic reaction to tetracycline due to concomitant tracheobronchitis with the first reaction [27]. As expected, a similar anaphylactic response was noted in this individual upon re-challenge. Although skin testing following anaphylaxis from tetracycline is rarely described, one report by Ogita et al. 2011 utilized a skin prick testing method using a 250 mg tetracycline capsule dissolved in 10 mg of saline [28]. A positive test with significant erythema and a wheal greater than 5 mm in diameter was observed; however, similar prick tests performed for both minocycline and doxycycline were negative [28]. Similarly, Fellner et al., 1965,
reported a positive direct skin test five days following an anaphylactic tetracycline reaction, as well as a positive hemagglutination assay test [29]. The majority of case reports did not report follow-up skin testing following anaphylaxis related to tetracycline administration [25–27,30,31], likely due to a lack of a standardized method for allergy confirmation as well as resources required for testing.

Table 2. Anaphylactic adverse effects caused by tetracycline.

| Publication   | Patient(s)   | Manifestations                    | Treatment and Outcome            |
|---------------|--------------|-----------------------------------|----------------------------------|
| Sakamoto 1956 | 43 yo male   | Loss of consciousness, convulsion, hypotension | Epinephrine, mephentermine, survived |
| Haas 1957     | 48 yo male   | Wheezing, hives, angioedema, hypotension | Ephedrine, diphenhydramine, aminophylline, survived |
| Fellner 1965  | 44 yo male   | Dyspnea, dizziness, flushing, tachycardia, urticaria | Epinephrine, survived |
| Barnett Jr. 1967 | 28 yo male | Wheezing, urticaria, neck pruritis | Epinephrine, diphenhydramine, survived |
| Singh 1977    | 25 yo male   | Widespread urticarial rash, cyanosis, hypotension, cardiac arrest | Not reported, expired |
| Steinbruegge 1980 | 26 yo male | Generalized urticaria, angioedema | Epinephrine, diphenhydramine, survived |
| Ogita 2011    | 17 yo female | Hives, dyspnea, generalized urticaria | Chlorpheniramine, hydrocortisone, prednisolone |

yo = year old.

3.2. Minocycline

Much of the literature surrounding allergic and adverse reactions to the tetracycline class is gleaned from case reports and case series. As previously mentioned, minocycline is most frequently used for the treatment of acne in the outpatient setting, although it does have other uses. Minocycline is a semisynthetic tetracycline and the reactions described with it will be divided into dermatological, pulmonary, rheumatologic, and other reactions associated with its use. Minocycline received United States Food and Drug Administration (FDA) approval in 1971, so much of the literature discussing its adverse effects dates from the 1980s and 1990s. In 1975, exanthema was reported in 86 of the 22,500 patients taking minocycline by Lederle Laboratories, the original manufacturer of minocycline [32]. Minocycline has been associated with a 13.6% incidence of adverse effects, ranging from nausea and vomiting to drug-hypersensitivity syndrome [33]. Between 1998 and 2003, 72 adverse events per million prescriptions of minocycline were reported by the FDA. Unfortunately, the incidence of adverse events to minocycline are six times more common than with doxycycline [34]. Unlike the other tetracyclines, because minocycline undergoes metabolism by the liver, the adverse effects could be due to changes in the cytochrome p450 system [35].

Minocycline hypersensitivity reactions are more commonly reported in females [36]. There has also been a suggestion that the mechanism of minocycline-induced reactions is due to minocycline or a metabolite acting as superantigen, which can lead to the overactivation of lymphocytes and a considerable release of cytokines [36]. These lymphocytes can move into the skin, causing dermatologic manifestations. The development of myocarditis has a similar mechanism to dermatological involvement. Minocycline metabolites bind to myocardial collagen, causing a T-cell-mediated cascade of inflammation [34]. Eosinophils are attracted to the inflammation and cause cardiac damage through the eosinophil cationic protein, eosinophil peroxidase, and the major basic protein. Myocarditis may present as hypersensitivity, eosinophilic myocarditis, or necrotizing eosinophilic myocarditis [37]. There are some reports of viral infections triggering a decreased metabolism or the formation of reactive metabolites from minocycline causing the proliferation of T-cells and cytokine release [34]. The reactive iminoquinone metabolite may contribute to this and activate specific viruses, such as human herpesvirus type 6, which can cause a late-phase reaction [38]. Tetracycline and doxycycline
are not metabolized to iminoquinone derivatives, which explains the proclivity of this reaction to be with minocycline. Reports of hypersensitivity syndrome from minocycline have described a fever that develops two to four weeks after onset of therapy, though it may take weeks or months for symptoms to resolve [39].

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome, which is associated with multiple agents, particular anticonvulsants, can also be seen with the use of minocycline. DRESS syndrome usually is associated with delayed onset and a prolonged course, with symptoms beginning between two weeks and two months after the initial medication exposure [34]. This syndrome is diagnosed by clinical criteria, which include fever, skin eruption, lymphadenopathy, fever, and facial edema, and systemic involvement can cause hepatitis, cerebral edema, and myocarditis. The risk of mortality of up to 10% with DRESS syndrome is often due to involvement with the liver and the heart [34]. The Fitzpatrick Skin Phototype Classification divides skin and eye color and characterizes them based on the skin’s reaction to sun exposure. These skin types (phototypes) are classified by the amount of melanin pigment in the skin. DRESS syndrome from minocycline is often associated with Phototypes V and VI, which includes individuals with darker skin (i.e., brown, dark brown, black) who rarely or never burn, possibly due to a melanin-minocycline complex [34,40]. Patients with these skin types might experience a more severe and prolonged course of DRESS syndrome. Previous research has also investigating the predisposition of patients of African descent who may have an altered variant of major histocompatibility complex haplotypes and an altered cytochrome p450 metabolism [34]. In a study by Maubec and colleagues, the accumulation of minocycline in patients’ skin who developed DRESS syndrome from minocycline was investigated [35]. The skin and plasma minocycline levels were obtained and genetic polymorphisms were investigated. Six of the eight patients had significant plasms levels of minocycline at 11 days and up to 17 months after the discontinuation of minocycline. Three patients had similar elevations in the skin at two to 17 months after minocycline was stopped [35]. High-performance liquid chromatography was performed and type III minocycline-related pigmentation was seen and may be due to the potential formation of a minocycline-melanin complex [35].

Additional dermatologic manifestations have been described as Sweet’s syndrome, which is an acute febrile neutrophilic dermatosis which has the characteristics of acute onset of fever, leukocytosis, and erythematous plaques with neutrophils [41]. Von den Driesch described major and minor criteria for diagnosis of Sweet’s syndrome in 1994. Major criteria include acute onset of painful erythematous plaques or nodules and neutrophilic infiltration of these plaques without leukocytoclastic vasculitis [41]. Minor criteria include a non-specific respiratory or gastrointestinal tract infection, or vaccination associated with inflammatory disease, malignancy, or pregnancy; malaise and fever; an elevated erythrocyte sedimentation rate, c-reactive protein, leukocytosis, and increased segmented-nuclear neutrophils; or an excellent response to treatment with corticosteroids or potassium iodide. At least one major and two minor criteria are required for diagnosis [41].

The adverse pulmonary manifestations seen with minocycline include lupus, hypersensitivity pneumonitis, and pleural effusions [42]. Eosinophilic pneumonia induced by minocycline has also been reported. In a case series of seven patients by Toyoshima et al., most patients presented with a dry cough, dyspnea, and fever [43]. On computed tomography (CT) scans of the chest, bilateral diffuse ground glass appearance was present in all patient, with some patients demonstrating micronodules and infiltrations. Eosinophils were also elevated in bronchoalveolar lavage specimens [43]. The authors concluded that minocycline-induced pneumonitis is manifested as eosinophilic pneumonia [43].

There have been additional reports of autoimmune syndromes caused by minocycline use. One such phenomenon has been described as a serum sickness, which is marked by fever, arthralgias, rash, and lymphadenopathy that resolve after drug discontinuation [44–47]. Serum sickness-like reactions often present within six to 21 days after administration of the causative agent [48]. Like other reports of reactions from minocycline, incidence in women appears to be greater than men. In two cases, the patients had previously tolerated tetracycline without incident [45]. In addition, one of these patients developed angioedema, which required epinephrine and also became worse when
taking non steroidal anti-inflammatory agents [45]. Reports of lupus-like syndromes have also been reported, which are distinguished by characteristics of systemic lupus erythematosus (SLE), in addition to positive anti-nuclear antibodies (ANA) [44,46,48]. In the reported cases, in addition to most of the patients being female, most were young women being treated for acne with minocycline who had arthralgias and had an elevated erythrocyte sedimentation rate and positive ANA. In the reported cases of minocycline-induced hepatitis, the incidence appears to be higher in males than females [44]. In addition to rash, fever, and arthralgias, transaminitis was present in all patients, along with a positive ANA in most patients. While hepatitis resolved after discontinuation of the causative agent, the resolution of liver enzymes was a much slower process when compared to the resolution of symptoms in minocycline-induced lupus [44].

Vasculitis has also been reported with similar symptoms as other autoimmune conditions, in addition to the manifestation of livedo reticularis. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) were present with a high titer in patients with minocycline-induced vasculitis [44]. In a report by Lan et al., autoimmune manifestations developed well after the initial insult [49]. Their case describes a 13-year-old girl who developed type 1 diabetes mellitus five months after the initial presentation, in addition to rapid-onset alopecia [49]. It has been suggested that viral reactivation may also play a role in the development of autoimmune conditions after DRESS syndrome. A report by Brown et al. described a 15-year-old female who presented with fever, erythroderma, lymphadenopathy, and facial swelling after a four-week course of minocycline [50]. Several months later, the patient was diagnosed with Graves disease, which required radioactive iodine thyroid ablation and type 1 diabetes mellitus. Another report showed the development of polyarteritis nodosa in a 23-year-old female [51]. The patient developed subcutaneous nodules, livedo reticularis, and pigmented lesions on her lower limbs and pANCA was positive. Finally, Rahman et al. described a case of rhabdomyolysis from minocycline in a 20-year-old female who was a professional ballet dancer [52]. In addition to erythematous eruptions, arthralgias, and facial swelling, she also developed significant rhabdomyolysis, which resolved with prednisone therapy.

There are a few reports of neurologic and psychiatric manifestations from minocycline [53–57]. An uncommon effect of minocycline was reported in one case where the patient developed depersonalization symptoms [53]. Depersonalization is characterized by a decrease in self-awareness, patients reporting disembodiment and emotional numbness. In this report, the patient felt disconnected and lost, with a feeling like she was disconnected from her body [53]. Upon discontinuation of minocycline, the symptoms resolved within two to three days. A report by Lefebvre and colleagues describes a patient with meningitis and cerebral edema induced by minocycline [54]. A 31-year-old female with human immunodeficiency virus (HIV) developed headaches, facial edema, and rash after taking minocycline, presenting with eosinophilia, leukocytosis, cytolytic hepatitis, and elevated c-reactive protein. A lumbar puncture showed lymphocytic meningitis and a CT scan of the head demonstrated diffuse cerebral edema [54]. Minocycline was discontinued and treatment was initiated with prednisolone 60 mg orally daily and the patient fully recovered after a slow taper of the prednisolone. This case suggests a potential risk of such a syndrome in the HIV population. A 35-year-old female developed non-enhancing foci with restricted diffusion on a brain magnetic resonance image (MRI) in the parietal and occipital lobes [55]. In addition to her neurological manifestations, she also demonstrated pulmonary involvement. The patient received corticosteroids and her neurologic abnormalities almost completely resolved by six weeks [55].

Another report describes anaphylaxis from minocycline in a 56-year-old female [56]. The patient presented with urticarial, angioedema, dyspnea, and hypotension on three separate occasions and was treated for anaphylaxis with chlorpheniramine, famotidine, hydrocortisone, and epinephrine. After the discovery of the causative agent, the patient fully recovered and has experience no further anaphylaxis [56]. Okano et al. 1995 described anaphylaxis in a middle-aged female within 30 min of receiving 100 mg of oral minocycline [57]. A minocycline scratch skin test was performed which revealed a large (13 × 16 mm) wheal and significant surrounding erythema [57]. This skin test helped to
confirm minocycline allergy due to concomitant medication skin test and oral challenge tests, revealing a negative result. Other reports of adverse reactions to minocycline are listed in Tables 3 and 4 [58–70].

**Table 3. Dermatological adverse effects caused by minocycline.**

| Publication   | Patient(s)          | Manifestations                                                                 | Treatment and Outcome                                                                 |
|---------------|---------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Shelley 1973  | 65 yo male          | Erythematous eruption, maculopapular rash, symptoms reappeared on re-challenge | Not reported                                                                          |
| Shimizu 1977  | 26 yo male          | Erythematous rash, eosinophilia, symptoms reappeared on re-challenge           | Corticosteroid                                                                        |
| LePaw 1983    | 48 yo male          | Erythematous and scaly eruption, symptoms reappeared on re-challenge           | Topical steroids, survived                                                              |
| Shoji 1987    | 36 yo male          | Stevens-Johnson Syndrome (fever, erythema multiforme-like eruptions, involvement of mouth and conjunctiva) | Oral corticosteroid, survived                                                          |
| Davies 1989   | 16 yo male          | Erythematous and exfoliative rash, fever, lymphadenopathy, leukopenia, transaminitis, positive streptococcal antibody | Not reported, survived                                                                  |
|               | 17 yo female        | Macular, exfoliative rash, fever, leukopenia, transaminitis, positive streptococcal antibody | Liver transplant, expired                                                              |
| Kaufmann 1994 | 35 yo female        | Rash, arthralgias, fever, lymphadenopathy, severe neutropenia                  | Prednisone, survived                                                                  |
| Parneix-Spake 1995 | 15 yo male     | Fever, diffuse pustular eruption, lymphadenopathy, leukocytosis, eosinophilia, transaminitis | Prednisone, expired (myocardial necrosis with interstitial eosinophilic infiltrate) |
|               | 17 yo female        | Fever, nonfollicular pustules, lymphadenopathy, dyspnea, leukocytosis, eosinophilia, transaminitis | Prednisone, survived                                                                  |
| Knowles 1996  | 6 patients (4 female/2 male) | Rash, hepatic involvement, lymphadenopathy, one patient developed Stevens-Johnson Syndrome (required liver transplant) | 5/6 patients received corticosteroids, all survived                                   |
| Okano 1996    | 27 yo female        | Erythematous eruption, dyspnea                                                 | Not reported                                                                            |
| MacNeil 1997  | 17 yo female        | Leukocytosis, eosinophilia, fever, transaminitis, macular eruption, lymphadenopathy, vesicular rash | IV methylprednisolone, survived                                                       |
| Colvin 2001   | 13 yo male          | Erythematous eruption, shock, leukocytosis, eosinophilia, transaminitis, lymphadenopathy | Antibiotics, methylprednisolone, survived                                              |
| Tsuruta 2006  | 20 yo female        | Fever, lymphadenopathy, eosinophilia, lymphocytosis, rash, transaminitis, symptoms reappeared on re-challenge | Prednisolone, survived                                                                 |
| Shaughnessy 2010 | 38 yo female      | Erythematous eruption and desquamation, fever, tachycardia, hypotension, increased CRP, eosinophilia, transaminitis, leukocytosis, myocardi | IV dexamethasone, IV methylprednisolone, plasmapheresis, rituximab, survived            |
| Kalai 2012    | 49 yo female        | Erythematous nodules and plaques, transaminitis                                | Prednisolone, Sweet Syndrome, survived                                               |
| Travassos 2012 | 19 yo female        | Subcutaneous erythematous nodules and pustules, fever, increased CRP and ESR, history of Hansen’s disease, erythema nodosum leprosum | Prednisolone and treatment for multi-bacillary leprosy, survived                      |
| Kanno 2014    | 60 yo female        | Erythematous rash, fever, periportal edema, lymphadenopathy, leukocytosis, eosinophilia, increased CRP and ESR | IV immunoglobulin, methylprednisolone, mechanical ventilation, percutaneous cardiopulmonary support and intra-aortic balloon pump, survived |
| Wu 2014       | 46 yo female        | Fever, arthralgia, transaminitis, lymphadenopathy, erythematous rash, eosinophilia, interstitial nephritis, myocardi | Methylprednisolone, expired (eosinophilic and giant cell myocarditis)                 |
| Lan 2016      | 13 yo female        | Eosinophilia, leukocytosis, fever, transaminitis                               | Required liver transplantation, survived                                               |
| Gowani 2018   | 18 yo female        | Macular rash, lymphadenopathy, fever, transaminitis, leukocytosis               | Prednisone, survived                                                                  |

C-reactive protein: CRP; ESR: erythrocyte sedimentation rate; IV: intravenous; Year old: yo.
### Table 4. Pulmonary adverse effects caused by minocycline.

| Publication      | Patient(s)                          | Manifestations                                                                 | Treatment and Outcome                      |
|------------------|-------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------|
| Toyoshima 1996   | 7 patients (4 female/3 male)        | Leukocytosis, elevated erythrocyte sedimentation rate and CRP, eosinophilia, ground glass opacities on computed tomography of chest | 3 patients required corticosteroids, all survived |
| Christodoulou 1999 | 16 yo female                        | Dyspnea, hypoxia, pulmonary infiltrates, transaminitis                           | Corticosteroids                             |
| Clayton 1992      | 26 yo female                        | Respiratory distress, erythematous eruption tonic-clonic seizures, transaminitis, eosinophilia | Mechanical ventilation, corticosteroids, survived |
| Parc 2002         | 28 yo female                        | Severe asthma exacerbation, conjunctival infiltrates, eosinophilia               | Prednisone, survived                        |
| Oddo 2003         | 54 yo female                        | Tachycardia, tachypnea, hypotension, fever, leukocytosis, increased CRP, eosinophilia | Mechanical ventilation, IV methylprednisolone, survived |
| Roca 2003         | 22 yo female                        | Acute respiratory distress syndrome, eosinophilia, rash, leukocytosis, bilateral diffuse infiltrate on chest radiograph | Mechanical ventilation, corticosteroids, antibiotics |

C-reactive protein: CRP; IV: intravenous; Year old: yo.

### 3.3. Doxycycline

Doxycycline is typically recognized as the most tolerable agent within the tetracycline class. Likewise, it is typically utilized to a greater degree compared with other tetracycline counterparts. The fairly limited body of literature describing doxycycline hypersensitivity and associated side effects reflects the overall tolerability of this agent. One such report of generalized urticaria following doxycycline was found to be dependent on the drug formulation itself, raising the possibility that an impurity or contaminant during doxycycline synthesis was to blame rather than the parent compound [71].

Few case reports have described serious reactions following doxycycline administration. A type I, immediate type anaphylactic reaction was described in a 71-year-old woman who received intravenous doxycycline in combination with beta-blocker administration during general anesthesia [72]. The patient experienced acute bronchospasm, hypotension, and urticaria, and required both intubation and medical support, which included epinephrine. While there is a lack of additional published reports regarding anaphylaxis, rare reports to the manufacturer (post-marketing surveillance) have described similar symptoms, such as bronchospasm and hypotension, that required medical intervention, including at least one fatality [72].

Most reports of adverse reactions following doxycycline therapy involve dermatologic reactions. Although more commonly reported with other tetracycline derivatives, skin eruptions have been reported with doxycycline use [73,74]. Of note is one case that described cutaneous eruptions after two full years of doxycycline therapy [73]. Erythematous plaques and nodules were noted on the patient’s extremities, and the patient’s sensitivity to this reaction was following an additional drug challenge a year later. Another case describes a 49-year-old male with recurrent, erythematous and purple patches on his hands and penis following intermittent oral doxycycline 100 mg twice daily for four months [74]. Once again, a 100 mg challenge dose confirmed this reaction when his patches returned within an hour.

Various reports, albeit rare, describe Stevens-Johnson syndrome (SJS) following doxycycline administration [75–78]. Although SJS typically results in epidermal detachment in less than 10% of the body surface area, morbidity and mortality can be significant. In addition to widespread cutaneous eruptions, typical presentation described with doxycycline-induced SJS typically also include oral mucosa lesions [75–77] and/or ophthalmic lesions [76,77]. Notably, reports of doxycycline-induced SJS were found to develop both immediately following doxycycline administration (within 24 h) [76] as well as within approximately 10–15 days [75,77] using standard doses of 200 mg per day or, in one case,
higher doses of 300 mg daily [77]. Despite prompt intervention, long-term ophthalmologic deficits from ocular involvement have been reported [76].

Other severe reactions have been infrequently reported with doxycycline use, including subacute cutaneous lupus erythematosus in an 84-year-old female despite sun avoidance [79]. Diffuse scaly papules and plaques were observed on her chest, abdomen, and extremities, while laboratory and pathology data suggested presumptive diagnosis of lupus erythematosus. DRESS syndrome has also been reported following three weeks of doxycycline treatment in an otherwise healthy 20-year-old female with acne [80]. Her initial presentation included papular eruptions on her face that later manifested into a widespread popular rash on her face, trunk, and extremities. She developed tonsillar edema with eosinophilia along with pulmonary edema and pneumonitis requiring intubation. Histological findings helped confirm DRESS syndrome diagnosis.

Shapiro et al. made recommendations as to who should avoid tetracycline antibiotics [81]. Minocycline should not be used in patients with a history of SLE or with a history of SLE in a first-degree relative. Caution should also be exercised with patients who have underlying hepatic or renal disease [81]. In addition, patients who develop a hypersensitivity reaction, serum sickness, or drug-induced lupus to any of the tetracyclines should avoid the class altogether. While many of the reactions to the tetracycline occur within the first few months of therapy, late reactions can occur years after the initiation of therapy [81].

4. Tetracycline Cross-Reactivity

Various studies have noted patients with a penicillin allergy also exhibiting an allergic response to tetracycline [26,29,30]. Some researchers have wonder if a penicillin allergy may predict tetracycline sensitivity. If such a relationship between penicillin and tetracycline allergy were to exist, this would be clinically significant, since tetracyclines are often chosen as an alternative therapy for infections in patients with penicillin allergy. However, an immunologic study of one such patient that utilized direct skin testing, passive transfer analysis, and hemagglutination testing determined two different and unrelated antibody-mediated responses for penicillin and tetracycline sensitivities, respectively [29]. These data contradict the presence of a direct relationship between penicillin and tetracycline allergy.

Few studies have directly evaluated tetracycline and minocycline testing for cross-sensitivity between the agents. Chan et al. completed two studies evaluating this relationship [82]. In the first study, six patients with a known fixed drug eruption from tetracycline were re-challenged with increasing doses of tetracycline until a reaction was seen. In the next study, the same patients were given either minocycline or chlortetracycline [82]. One of the four patients given minocycline had a reaction and one of the two patients given chlortetracycline reacted. The authors hypothesized, based on a limited data set, that one in four patients with a fixed drug eruption with tetracycline would react to another agent in the class [82]. Another study described similar cross-reactivity between doxycycline and minocycline. A patient with a prior history of fixed drug reaction due to doxycycline had a recurrence of this reaction when minocycline was administered eight months following the initial reaction. Each of these reactions occurred within hours of administration [83]. Other studies did not report the same incidence of cross-reactivity between tetracycline, minocycline, and doxycycline. One such report describes two cases of tetracycline-induced balanitis that did not recur with subsequent doxycycline or minocycline oral challenges [84]. Likewise, these limited reports indicate that tetracycline cross-reactivity due to dermatologic manifestations can be variable.

5. Conclusions

Compared to other classes of antibiotics, the tetracyclines collectively have lower rates of immediate-type IgE-mediated hypersensitivity reactions, although various other serious allergic reactions have been described. Primary literature reports of type I allergic reactions due to tetracycline derivatives are limited to case reports. Minocycline carries the greatest risk of serious, non-IgE mediated reactions that are often dermatologic and pulmonary in nature, although many reports
were in patients who received prolonged courses of therapy. Tetracycline has been associated with less severe dermatologic reactions, such as fixed drug reaction, while doxycycline may carry the best overall safety profile regarding allergic reaction potential. Data describing allergic cross-reactivity within the tetracycline class is primarily limited to describing the development of fixed drug reactions.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nelson, M.L.; Levy, S.B. The history of the tetracyclines. *Ann. N. Y. Acad. Sci.* **2011**, *1241*, 17–32. [CrossRef] [PubMed]
2. Verbalis, J.G.; Goldsmith, S.R.; Greenberg, A.; Korzelius, C.; Schrier, R.W.; Sterns, R.H.; Thompson, C.J. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. *Am. J. Med.* **2013**, *126*, S1–S42. [CrossRef] [PubMed]
3. Mandell, L.A.; Wunderink, R.G.; Anzueto, A.; Bartlett, J.G.; Campbell, G.D.; Dean, N.C.; Dowell, S.F.; File, T.M.; Musher, D.M.; Niederman, M.S.; et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin. Infect. Dis.* **2007**, *44*, S27–S72. [CrossRef] [PubMed]
4. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. *Clin. Infect. Dis.* **2011**, *52*, e18–e55. [CrossRef] [PubMed]
5. Stevens, D.L.; Bisno, A.L.; Chambers, H.F.; Dellinger, E.P.; Goldstein, E.J.; Gorbach, S.L.; Hirschmann, J.V.; Kaplan, S.L.; Montoya, J.G.; Wade, J.C. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin. Infect. Dis.* **2014**, *59*, e10–e52. [CrossRef]
6. Zaenglein, A.L.; Pathy, A.L.; Schlosser, B.J.; Alikhan, A.; Baldwin, H.E.; Berson, D.S.; Bowe, W.P.; Graber, E.M.; Harper, J.C.; Kang, S.; et al. Guidelines of care for the management of acne vulgaris. *J. Am. Acad. Dermatol.* **2016**, *74*, 945–973. [CrossRef]
7. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm. Rep.* **2015**, *64*, 1–140.
8. Centers for Disease Control and Prevention. *Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers*, 5th ed. Available online: https://www.cdc.gov/ticks/tickborne diseases/Tickborne Diseases-P.pdf (accessed on 4 June 2019).
9. Ory, E.M. The tetracyclines. *Med. Clin. N. Am.* **1970**, *54*, 1173–1186. [CrossRef]
10. Fiumara, N.J.; Yaqub, M. Pigmented penile lesions (fixed drug eruptions) associated with tetracycline therapy for sexually transmitted diseases. *Sex. Transm. Dis.* **1981**, *8*, 23–25. [CrossRef]
11. Csonka, G.W.; Rosedale, N.; Walkden, L. Balanitis due to fixed drug eruption associated with tetracycline therapy. *Br. J. Vener. Dis.* **1971**, *47*, 42–44. [CrossRef]
12. Broden, M.B. Fixed-drug eruption to tetracycline. *Arch. Dermatol.* **1970**, *101*, 621. [CrossRef]
13. Dodds, P.R.; Chi, T. Balanitis as a fixed drug eruption to tetracyclines. *J. Urol.* **1985**, *133*, 1044–1045. [CrossRef]
14. Delaney, T.J. Tetracycline-induced fixed drug eruptions. *Br. J. Dermatol.* **1970**, *83*, 357. [CrossRef]
15. Murray, V.K.; DeFeo, C.P. Introraol fixed drug eruption following tetracycline administration. *J. Periodontol.* **1982**, *53*, 267–268. [CrossRef]
16. Ziprowski, L.; Glazer, I. Dermatitis medicamentosa apparently due to tetracycline. *J. Allergy Clin. Immunol.* **1958**, *29*, 336–339.
17. Tarnowski, W.M. Fixed drug eruption due to tetracycline. *Acta Derm. Venereol.* **1970**, *50*, 117–118. [CrossRef]
18. Armati, R.P. Fixed drug eruption due to tetracycline—A report of a case. *Australas. J. Dermatol.* **1973**, *17*, 75–77. [CrossRef]
19. Yap, L.M.; Foley, P.A.; Crouch, R.B.; Baker, C.S. Drug-induced solar urticaria due to tetracycline. *Australas. J. Dermatol.* **2000**, *41*, 181–184. [CrossRef]
20. Bean, S.F. Acneiform eruption from tetracycline. *Br. J. Dermatol.* **1971**, *85*, 585–586. [CrossRef]
21. Dubowitz, L.M.S.; Dubowitz, V. Acute dermatomyositis presenting with pulmonary manifestations. Arch. Dis. Child. 1964, 39, 293–296. [CrossRef]
22. Minkin, W.; Cohen, H.J.; Frank, S.B. Fixed-drug eruption due to tetracycline. Arch. Dermatol. 1969, 100, 749. [CrossRef]
23. Parish, L.C.; Witkowski, J.A. Pulsating fixed drug eruption due to tetracycline. Acta Derm. Venereol. 1978, 58, 545–547.
24. Calnan, C.D.; Lister, D.J.M. Anaphylactoid purpura from tetracycline. Trans. St. Johns Hosp. Dermatol. Soc. 1960, 44, 69–72.
25. Sakamoto, A. Anaphylactoid reaction to intramuscular tetracycline hydrochloride: Report of a case. Calif. Med. 1956, 84, 55–56.
26. Steinbruegge, J.M.; Judson, F.N. Type 1 allergic reaction to orally administered tetracycline hydrochloride. Sex. Transm. Dis. 1980, 7, 193–194. [CrossRef]
27. Barnett, C.F., Jr. Anaphylactoid reaction to orally administered tetracycline. South. Med. J. 1967, 60, 963. [CrossRef]
28. Ogita, A.; Takada, K.; Kawana, S. Case of anaphylaxis due to tetracycline hydrochloride. J. Dermatol. 2011, 38, 597–599. [CrossRef]
29. Fellner, M.J.; Baer, R.L. Anaphylactic reaction to tetracycline in a penicillin-allergic patient. JAMA 1965, 192, 997–998. [CrossRef]
30. Haas, R. Anaphylactoid reaction to oral tetracycline. J. Maine Med. Assoc. 1957, 48, 85.
31. Singh, C.V.; Grover, V.; Kamra, G.L. Fatal anaphylactic reaction to tetracycline in the postoperative period. Anaesthesia 1977, 32, 268–269. [CrossRef]
32. Shimizu, Y.; Shimao, S. A case of minocycline-induced fixed drug eruption. J. Dermatol. 1977, 4, 73–76. [CrossRef]
33. Clayton, B.D.; Hitchcock, M.G.; Williford, P.M. Minocycline hypersensitivity with respiratory failure. Arch. Dermatol. 1999, 135, 139–140.
34. Shaughnessy, K.K.; Bouchard, S.M.; Mohr, M.R.; Herre, J.M.; Salkey, K.S. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J. Am. Acad. Dermatol. 2010, 62, 315–318. [CrossRef]
35. Maubec, E.; Wolkenstein, P.; Loriot, M.A.; Wechsler, J.; Mulot, C.; Beaune, P.; Revuz, J.; Roujeau, J.C. Minocycline-induced DRESS: Evidence for accumulation of the culprit drug. Dermatology 2008, 216, 200–204. [CrossRef]
36. MacNeil, M.; Haase, D.A.; Tremaine, R.; Marrie, T.J. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: A severe adverse reaction to minocycline. J. Am. Acad. Dermatol. 1997, 36, 347–350. [CrossRef]
37. Kanno, K.; Sakai, H.; Yamada, Y.; Iizuka, H. Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis. J. Dermatol. 2014, 41, 160–162. [CrossRef]
38. Tsuruta, D.; Someda, Y.; Sowa, J.; Kobayashi, H.; Ishii, M. Drug hypersensitivity syndrome caused by minocycline. J. Cutan. Med. Surg. 2006, 10, 131–135. [CrossRef]
39. Colvin, J.H.; Sheth, A.P. Minocycline hypersensitivity syndrome with hypotension mimicking septic Shock. Pediatr. Dermatol. 2001, 18, 295–298. [CrossRef]
40. Fitzgerald, T.B. The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1988, 124, 869–871. [CrossRef]
41. Von den Driesch, P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J. Am. Acad. Dermatol. 1994, 31, 535–536. [CrossRef]
42. Oddo, M.; Liaude, L.; Lepori, M.; Brocard, A.F.; Schaller, M.D. Relapsing acute respiratory failure induced by minocycline. CHEST 2003, 123, 2146–2148. [CrossRef]
43. Toyoshima, M.; Sato, A.; Hayakawa, H.; Taniguchi, M.; Imokawa, S.; Chida, K. A clinical study of minocycline-induced pneumonitis. Intern. Med. 1996, 35, 176–179. [CrossRef]
44. Elkayam, O.; Yaron, M.; Caspi, D. Minocycline-induced autoimmune syndromes: An overview. Semin. Arthritis Rheum. 1999, 28, 392–397. [CrossRef]
45. Levenson, T.; Masood, D.; Patterson, R. Minocycline-induced serum sickness. Allergy Asthma Proc. 1996, 17, 79–81. [CrossRef]
46. Knowles, S.R.; Shapiro, L.; Shear, N.H. Serious adverse reactions induced by minocycline. *Arch. Dermatol.* 1996, 132, 934–939. [CrossRef]
47. Malakar, S.; Dhar, S.; Shah Malakar, R. Is serum sickness an uncommon adverse effect of minocycline treatment? *Arch. Dermatol.* 2001, 137, 100–101. [CrossRef]
48. Clark, A.K.; Shi, V.Y.; Sivamani, R.K. Unique urticarial presentation of minocycline-induced lupus erythematosus. *Dermatol. Online J.* 2017, 23, 1–5.
49. Lan, J.; Lahoti, A.; Lew, D.B. A severe case of minocycline-induced DRESS resulting in liver transplantation. *Ann. Allergy Asthma Immunol.* 2016, 116, 367–368. [CrossRef]
50. Brown, R.J.; Rother, K.I.; Artman, H.; Mercurio, M.G.; Wang, R.; Looney, R.J.; Cowen, E.W. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. *Arch. Dermatol.* 2009, 145, 63–66. [CrossRef]
51. Pelletier, F.; Puzenat, E.; Blanc, D.; Humbert, P.; Aubin, F. Minocycline-induced cutaneous polyarteritis nodosa with antineutrophil cytoplasmic antibodies. *Eur. J. Dermatol.* 2003, 13, 396–398.
52. Rahman, Z.; Weinberg, J.; Scheinfeld, N. Minocycline hypersensitivity syndrome manifesting with rhabdomyolysis. *Int. J. Dermatol.* 2002, 41, 530–531. [CrossRef]
53. Shamout, Y.; Sigal, A.; Litvinov, I.V. Minocycline-induced transient depersonalization: A case report. *SAGE Open Med. Case Rep.* 2019, 7. [CrossRef]
54. Lefebvre, N.; Forestier, E.; Farhi, D.; Zadeh Mahsa, M.; Remy, V.; Lesens, O.; Christmann, D.; Hansmann, Y. Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: A case report. *J. Med. Case Rep.* 2007, 1, 22. [CrossRef]
55. Settgast, A.M.; Groth, T.; Gartner, E. Minocycline-induced central nervous system–pulmonary hypersensitivity syndrome. *Int. J. Dermatol.* 2003, 42, 316–317. [CrossRef]
56. Jang, J.W.; Bae, Y.J.; Kim, Y.G.; Jin, Y.J.; Park, K.S.; Cho, Y.S.; Moon, H.B.; Kim, T.B. A case of anaphylaxis to oral minocycline. *J. Korean Med. Sci.* 2010, 25, 1231–1233. [CrossRef]
57. Okano, M.; Imai, S. Anaphylactoid symptoms due to oral minocycline. *J. Korean Med. Sci.* 1999, 15, 1471–1473. [CrossRef]
58. Christieodoulou, C.S.; Emmanuel, P.; Ray, R.A.; Good, R.A.; Schnapf, B.M.; Cawkwell, G.D. Respiratory distress due to minocycline-induced pulmonary lupus. *Chest* 1999, 115, 154–159. [CrossRef]
59. Davies, M.G.; Kersey, P.J. Acute hepatitis and exfoliative dermatitis associated with minocycline. *BMJ* 1989, 298, 1523–1524. [CrossRef]
60. Gowani, F.; Gehrs, B.; Scordino, T. Drug-induced hypersensitivity syndrome: A clinical, radiologic, and histologic mimic of lymphoma. *Case Rep. Hematol.* 2018, 2018, 7037352. [CrossRef]
61. Kalai, C.; Brand, R.; Yu, L. Minocycline-induced Sweet syndrome (acute febrile neutrophilic dermatosis). *J. Am. Acad. Dermatol.* 2012, 67, e289–e291. [CrossRef]
62. Kaufmann, D.; Pichler, W.; Beer, J.H. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and autoimmune sequelae associated with minocycline. *Allergol. Et. Immunopathol.* 2013, 107–110. [CrossRef]
63. Parneix-Spake, A.; Bastuji-Garin, S.; Lobut, J.B.; Erner, J.; Guyet-Rousset, P.; Revuz, J.; Roujeau, J.C. Minocycline-induced urticarial presentation of minocycline-induced lupus erythematosus. *Dermatol. Online J.* 2017, 23, 1–5.
64. Travassos, R.R.; Antunes, J.; Pacheco, D.; Almeida, L.S.; Filipe, P.; Marques, M.S. Erythema nodosum leprosum associated with minocycline. *Acta Dermatovenerol. APA* 2012, 21, 39–41.
65. Wu, P.A.; Anadkat, M.J. Fever, eosinophilia, and death: A case of minocycline hypersensitivity. *Cutis* 2014, 93, 107–110.
66. Deluze, R.A.; Girard, J.P. An unusual case of allergy to doxycycline. *Allergol. Et. Immunopathol.* 1992, 20, 215–216.
72. Raeder, J.C. Anaphylactoid reactions caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. *Drug Intell. Clin. Pharm.* 1984, 18, 481–482. [CrossRef]
73. Weinstein, M.; Laxer, R.; Debozs, J.; Somers, G. Doxycycline-induced cutaneous inflammation with systemic symptoms in a patient with acne vulgaris. *J. Cutan. Med. Surg.* 2013, 17, 283–286. [CrossRef]
74. Gul, U.; Goulu, M.; Soylu, S.; Kaya, I. Doxycycline-induced fixed drug eruption. *J. Dermatol. Treat.* 2008, 19, 126–127. [CrossRef]
75. Cac, N.N.; Messingham, M.J.; Sniezek, P.J.; Walling, H.W. Stevens-Johnson syndrome induced by doxycycline. *Cutis* 2007, 79, 119–122.
76. Lau, B.L.; Mutyala, D.; Dhalival, D. A case report of doxycycline-induced Stevens-Johnson syndrome. *Cornea* 2011, 30, 595–597. [CrossRef]
77. Curley, R.K.; Verbov, J.L. Stevens-Johnson syndrome due to tetracyclines-a case report (doxycycline) and review of the literature. *Clin. Exp. Dermatol.* 1987, 12, 124–125. [CrossRef]
78. Gallais, V.; Randrianjohanny, A.; Robineau, M.; Laroche, L. Stevens-Johnson syndrome caused by doxycycline. *Presse Med.* 1997, 26, 855.
79. Miller, K.K.; Chu, J.; Patel, R.; Kamino, H. Drug-induced subacute cutaneous lupus erythematosus related to doxycycline. *Dermatol. Online J.* 2011, 17, 3.
80. Robles, D.T.; Leonard, J.L.; Compton, N.; Waghmare, A.; McDonough, K.A.; George, E.; Wolgamot, G.; Fleckman, P. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. *Dermatology* 2008, 217, 23–26. [CrossRef]
81. Shapiro, L.E.; Knowles, S.R.; Shear, N.H. Comparative safety of tetracycline, minocycline, and doxycycline. *Arch. Dermatol.* 1997, 133, 1224–1230. [CrossRef]
82. Chan, H.L.; Wong, S.N.; Lo, F.L. Tetracycline-induced fixed drug eruptions: Influence of dose and structure of tetracyclines. *J. Am. Acad. Dermatol.* 1985, 13, 302–304. [CrossRef]
83. Correia, O.; Delgado, L.; Polônia, J. Genital fixed drug eruption: Cross-reactivity between doxycycline and minocycline. *Clin. Exp. Dermatol.* 1999, 24, 137. [CrossRef]
84. Bargman, H. Lack of cross-sensitivity between tetracycline, doxycycline, and minocycline with regard to fixed drug sensitivity to tetracycline. *J. Am. Acad. Dermatol.* 1984, 11, 900–902. [CrossRef]